On 27 October 2011, orphan designation (EU/3/11/925) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for mifepristone for the treatment of hypercortisolism (Cushing's syndrome) of endogenous origin.
The sponsorship was transferred to Dr Ulrich Granzer, Germany, in December 2012 and subsequently to FGK Representative Service GmbH, Germany, in October 2013 and to Dr Ulrich Granzer, Germany, in August 2015.
|Disease / condition||
Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin
|Date of decision||
|Orphan decision number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.